ClinicalTrials.gg
RecruitingNCT06364735Updated Aug 19, 2024

Entities and Variables Related to Catch-up Growth

An observational study in Celiac Disease in Children, sponsored by ASST Fatebenefratelli Sacco. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by ASST Fatebenefratelli Sacco · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Celiac Disease with a site in Italy — 14 open to participants now, 16 under way, none of them phase 3. Celiac Disease · Italy.

Planned enrollment
2nd of 26
900 · median 207
Started
2024
with 2 others
Observational
26 of 61
9 open now
Primary completion
2024-12
later than 1 of 15 live
Registered
52nd of 61
by date
Lead sponsor
1 of 61
ASST Fatebenefratelli Sacco

Among the 61 studies in Celiac Disease with a site in Italy, this one is the 2nd largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2024, is one of 26 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 52nd registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

14 of the 61 studies in Celiac Disease with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Celiac Disease with a site in Italy, or all of them as a file.
02

Study summary

A retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year follow-up. The only extrapolation of the data collected in anonymized form from the medical records of patients who match the necessary study criteria will be planned in order to achieve this aim. A 900-patient sample size will be planned.

03

Conditions studied

  • Celiac Disease in Children

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Childhood celiac disease patients on a gluten-free diet

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • celiac disease diagnosis established at the V. Buzzi Children\'s Hospital in Milan between January 2010 and December 2020, excluding the extremes, in accordance with the ESPGHAN 2012 or 2020 recommendations.

Exclusion criteria

Exclusion Criteria:

  • patients with unclear or non-specific duodenal histological alterations (e.g., atrophy with unavailable or negative specific antibodies for celiac disease);
  • patients with additional chronic illnesses;
  • absence of the data required for the study;
  • patients with IgA deficiency, defined as IgA \<20 mg/dl in children \<3 years old or with levels that are below normal for their age.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
900 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Measure the catch-up growth degree.

    Changes in the auxological weight variable in pediatric patients with celiac disease were measured 6 months and 24 months after they started a gluten-free diet. The change was expressed as an average daily weight increase and compared with the average increase expected for sex and age in a healthy population extrapolated from validated curves (Cacciari).

    Time frame: 6 and 24 month

Secondary outcomes

  1. Calculate the degree of catch-up growth

    Variation in the auxological variable of height in pediatric patients with celiac disease, measured as variation in the standard deviation of this variable compared to reference values for age and sex extrapolated from validated curves (Cacciari curves), at six and twenty-four months after the start of the gluten-free diet.

    Time frame: 6 and 24 month

Other outcomes

  1. Exploratory objectives 1

    Identify the correlation between the degree of catch-up growth and the persistence of the symptoms, MC-related antibody positivity and the level of diet adherence at the 6- and 24-month follow-up

    Time frame: 6 and 24 month

  2. Exploratory objectives 2

    Define the degree of celiac disease's clinical, endoscopic, histological, and serological severity at the time the sample was diagnosed, and then correlate it to the degree of catch-up growth that occurred 6 and 24 months after the gluten-free diet was started

    Time frame: 6 and 24 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2024, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 15, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Jan 1, 2025
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06364735
Lead sponsor
ASST Fatebenefratelli Sacco
Responsible party
Elena Groppali (MD, ASST Fatebenefratelli Sacco) — Principal investigator
First posted
Apr 15, 2024
Start date
Jul 1, 2024
Primary completion
Dec 1, 2024 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Aug 19, 2024

Study contacts

Elena Groppali, MD
Contact
elena.groppali@asst-fbf-sacco.it
00390263631
Elena Groppali, MD
Contact
elena.groppali@asst-fbf-sacco.it
00390263635331

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion